MA38488A1 - Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate - Google Patents

Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate

Info

Publication number
MA38488A1
MA38488A1 MA38488A MA38488A MA38488A1 MA 38488 A1 MA38488 A1 MA 38488A1 MA 38488 A MA38488 A MA 38488A MA 38488 A MA38488 A MA 38488A MA 38488 A1 MA38488 A1 MA 38488A1
Authority
MA
Morocco
Prior art keywords
quinuclidin
thiazol
propan
fluorophenyl
forms
Prior art date
Application number
MA38488A
Other languages
English (en)
Inventor
Craig Siegel
Jin Zhao
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50543351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA38488A1 publication Critical patent/MA38488A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouvelles formes de sels de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate utiles en tant qu'un inhibiteur de synthase de glucosylcéramide (gcs) et pour le traitement de maladies métaboliques telles que les maladies lysosomales, soit seul, soit en association avec une thérapie de remplacement enzymatique, et pour le traitement du cancer.
MA38488A 2013-03-15 2014-03-14 Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate MA38488A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791706P 2013-03-15 2013-03-15
PCT/US2014/027081 WO2014152215A1 (fr) 2013-03-15 2014-03-14 Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate

Publications (1)

Publication Number Publication Date
MA38488A1 true MA38488A1 (fr) 2017-10-31

Family

ID=50543351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38488A MA38488A1 (fr) 2013-03-15 2014-03-14 Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate

Country Status (34)

Country Link
US (1) US9518049B2 (fr)
EP (1) EP2970250B1 (fr)
JP (1) JP6438455B2 (fr)
KR (1) KR102302064B1 (fr)
CN (1) CN105189490A (fr)
AR (1) AR095435A1 (fr)
AU (1) AU2014240028B2 (fr)
BR (1) BR112015022907B1 (fr)
CA (1) CA2906691A1 (fr)
CL (1) CL2015002701A1 (fr)
DK (1) DK2970250T3 (fr)
EA (1) EA037527B1 (fr)
ES (1) ES2872326T3 (fr)
HK (1) HK1214821A1 (fr)
HR (1) HRP20210692T1 (fr)
HU (1) HUE054349T2 (fr)
IL (1) IL241229B (fr)
JO (1) JO3713B1 (fr)
LT (1) LT2970250T (fr)
MA (1) MA38488A1 (fr)
MX (1) MX370178B (fr)
MY (1) MY181766A (fr)
PH (1) PH12015502021A1 (fr)
PL (1) PL2970250T3 (fr)
PT (1) PT2970250T (fr)
RS (1) RS61852B1 (fr)
SA (1) SA515361078B1 (fr)
SG (1) SG11201507054YA (fr)
SI (1) SI2970250T1 (fr)
TN (1) TN2015000427A1 (fr)
TW (1) TWI713438B (fr)
UY (1) UY35439A (fr)
WO (1) WO2014152215A1 (fr)
ZA (1) ZA201506602B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201804952QA (en) * 2013-12-11 2018-07-30 Genzyme Corp Glucosylceramide synthase inhibitors
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
JP2022519131A (ja) 2019-02-04 2022-03-18 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置
AU2021215396A1 (en) * 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat
WO2022024062A1 (fr) 2020-07-30 2022-02-03 Genzyme Corporation Procédés de réduction de la concentration en glycosphingolipides dans le tissu cérébral et procédés de traitement de maladies neurodégénératives impliquant ces derniers
WO2022215083A1 (fr) * 2021-04-05 2022-10-13 Msn Laboratories Private Limited, R&D Center Formes à l'état solide de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl) carbamate ou de sels et procédé de préparation associé

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
WO2010091104A1 (fr) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibiteurs de la glucosylcéramide synthase
EP3482767B1 (fr) 2009-08-28 2021-10-06 Icahn School of Medicine at Mount Sinai Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide
PT2685986T (pt) * 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase

Also Published As

Publication number Publication date
JP2016513679A (ja) 2016-05-16
BR112015022907A8 (pt) 2019-11-26
SG11201507054YA (en) 2015-10-29
BR112015022907B1 (pt) 2022-07-12
PH12015502021A1 (en) 2016-01-11
UY35439A (es) 2014-10-31
KR102302064B1 (ko) 2021-09-13
SA515361078B1 (ar) 2018-06-14
EP2970250A1 (fr) 2016-01-20
AU2014240028B2 (en) 2018-08-02
HRP20210692T1 (hr) 2021-06-11
PL2970250T3 (pl) 2021-12-06
PT2970250T (pt) 2021-05-07
US20160039805A1 (en) 2016-02-11
TW201502127A (zh) 2015-01-16
TWI713438B (zh) 2020-12-21
HUE054349T2 (hu) 2021-09-28
JP6438455B2 (ja) 2018-12-12
BR112015022907A2 (pt) 2017-07-18
LT2970250T (lt) 2021-05-10
MY181766A (en) 2021-01-06
MX370178B (es) 2019-12-04
ZA201506602B (en) 2023-04-26
ES2872326T3 (es) 2021-11-02
SI2970250T1 (sl) 2021-06-30
US9518049B2 (en) 2016-12-13
NZ712659A (en) 2020-11-27
KR20150132333A (ko) 2015-11-25
RS61852B1 (sr) 2021-06-30
TN2015000427A1 (en) 2017-01-03
JO3713B1 (ar) 2021-01-31
AU2014240028A1 (en) 2015-10-15
IL241229A0 (en) 2015-11-30
MX2015012295A (es) 2016-05-16
CL2015002701A1 (es) 2016-03-18
CA2906691A1 (fr) 2014-09-25
EA037527B1 (ru) 2021-04-08
EP2970250B1 (fr) 2021-04-21
HK1214821A1 (zh) 2016-08-05
CN105189490A (zh) 2015-12-23
AR095435A1 (es) 2015-10-14
EA201591706A1 (ru) 2016-02-29
IL241229B (en) 2019-12-31
WO2014152215A1 (fr) 2014-09-25
DK2970250T3 (da) 2021-07-12

Similar Documents

Publication Publication Date Title
MA38488A1 (fr) Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate
MA35023B1 (fr) Inhibiteurs de la glucosylcéramide synthase
MA37975B2 (fr) Inhibiteurs de synthase de glucosylcéramide
PH12016502167A1 (en) Hdl theraphy markers
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
BR112018071585A2 (pt) formulações de um inibidor de lsd1
MX2019007276A (es) Composiciones y métodos para mejora o aumento de la producción de ifn tipo i.
CL2015003731A1 (es) Inhibidores de bromodominios
EA201890641A3 (ru) Стимуляторы sgc
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
PH12019501010A1 (en) Arginase inhibitor combination therapies
EA201791993A1 (ru) Способы лечения протеинопатий
CA3010708A1 (fr) Procedes d'administration d'hepcidine
SG10201804952QA (en) Glucosylceramide synthase inhibitors
CL2015000110A1 (es) Metodo de prevencion o tratamiento de una respuesta farmacodinamica adversa inducida por opioides; unidad de dosis farmaceutica que comprende buprenorfina y otro opioide; kit farmaceutico. (divisional de la solicitud n°2790-2014).
MX2019005627A (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.
MX2019014306A (es) Agente para reducir la cantidad de proteina beta amiloide.
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
PH12016501491A1 (en) Targeted therapeutics
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical